Home > Healthcare > Medical Devices > Diagnostic Devices > Enteric Disease Testing Market

Enteric Disease Testing Market - By Disease (Bacterial [C. difficile, E. coli, Salmonella, Campylobacter], Viral [Rotavirus], Parasitic [Amebiasis, Giardiasis]), Test Type (Immunoassay, Molecular, Conventional), End-use – Global Forecast, 2024 – 2032

  • Report ID: GMI4024
  • Published Date: Feb 2024
  • Report Format: PDF

Enteric Disease Testing Market Size

Enteric Disease Testing Market size was valued at around USD 3.7 billion in 2023 and is estimated to expand at 3.9% CAGR from 2024 to 2032. This high market growth can be primarily attributed to numerous factors including increasing prevalence of enteric diseases, growing concerns about food safety, continuous advancements in diagnostic technologies, and increasing healthcare expenditure and awareness across the globe.

Enteric Disease Testing Market

Moreover, enteric diseases, which are infections of the gastrointestinal system caused by bacteria, viruses, or parasites, are prevalent across the world. Enteric diseases can be transmitted by contaminated food and water sources, inadequate sanitation, and close human-to-human contact. The growing prevalence of enteric infections demands accurate diagnostic tests to identify the causative agents, advise proper therapy, and prevent future transmission.

For instance, as per the stats reported by Centers for Disease Control and Prevention, in 2022 there were an estimated 9.4 million diseases, 56,000 hospital admissions, and 1,350 fatalities in the U.S. attributed to infections from major foodborne pathogens.

Moreover, public health surveillance systems are crucial in monitoring the prevalence, and trends of enteric disease on an individual, national, and globally scale. Surveillance data reveal insights into disease outbreaks, new pathogens, antibiotic resistance patterns, and healthcare use trends, allowing for prompt interventions and resource allocation methods. Enteric disease testing is a critical component of public health surveillance activities, enabling early diagnosis, containment, and control of infectious diseases, thereby contribute to the growth of the enteric disease testing market.

Enteric disease testing refers to the diagnostic evaluation conducted to identify infections and illnesses affecting the gastrointestinal tract, commonly known as the enteric system. The enteric system encompasses various organs and structures involved in the digestion and absorption of food, including the stomach, small intestine, large intestine (colon), rectum, and anus.

Enteric Disease Testing Market Trends

Growing trend towards the adoption of molecular diagnostics technique, surging demand for point-of-care testing, rise in foodborne illness surveillance, increasing need for integrated automation and robotics, and growing trends for personalized medicine and host response testing, among other factors are propelling the industry growth.

  • There is a growing trend in intestinal disease testing to incorporate molecular diagnostic techniques such as PCR technologies and nucleic acid amplification tests (NAATs). Molecular approaches provide greater sensitivity, specificity, and rapid detection of enteric infections than classic culture-based methods, thus to their increased usage in clinical laboratories and healthcare settings.
  • Moreover, laboratory automation and robotic systems are being increasingly integrated into enteric disease testing workflows to streamline sample processing, improve testing throughput, and reduce turnaround times. Automated platforms for sample preparation, nucleic acid extraction, and assay setup enhance testing efficiency, minimize manual errors, and optimize laboratory resources.

Enteric Disease Testing Market Analysis

Enteric Disease Testing Market, By Disease, 2021 – 2032 (USD Billion)

The market by disease is categorized into bacterial enteric disease, viral enteric disease, and parasitic enteric diseases. The bacterial enteric disease segment is further divided into C. difficile, E. coli, salmonella, campylobacter, listeria, and shigellosis. The viral enteric disease segment is further bifurcated into rotavirus infection, and norovirus infection. The parasitic enteric disease segment is further divided into giardiasis, amebiasis, and cryptosporidiosis. The bacterial enteric disease segment accounted for majority share and was valued at over USD 2.1 billion revenue in 2023.

  • Bacterial enteric diseases, such as salmonellosis, shigellosis, campylobacteriosis, and Escherichia coli (E. coli) infections, are prevalent worldwide. The high incidence of bacterial enteric infections, especially in developing countries with poor sanitation and hygiene standards, underscores the need for effective diagnostic testing to identify the causative agents and implement appropriate treatment and control measures.
  • Further, ongoing advancements in diagnostic technologies, such as polymerase chain reaction (PCR) assays, multiplex panels, and next-generation sequencing (NGS) platforms, enhance the sensitivity, specificity, and speed of bacterial enteric disease testing. Molecular methods enable the simultaneous detection of multiple bacterial pathogens from clinical specimens, improving diagnostic accuracy and efficiency in clinical microbiology laboratories and public health laboratories.
Enteric Disease Testing Market, By Test Type (2023)

Based on test type, the enteric disease testing market is segmented into immunoassay, molecular, conventional, chromatography & spectrometry, and other test types. The immunoassay segment held leading revenue share in 2023 and is anticipated to reach USD 1.9 billion by 2032.

  • Immunoassays offer high sensitivity and specificity in detecting specific antigens or antibodies associated with enteric pathogens. These assays can accurately identify target molecules, such as bacterial toxins, viral antigens, or parasitic antigens, present in patient samples, facilitating rapid and reliable diagnosis of enteric diseases.
  • Moreover, immunoassays often provide rapid results compared to traditional culture-based methods or molecular diagnostics. Rapid diagnostics tests (RDTs) based on immunoassay principles allow for on-site testing and immediate detection of enteric pathogens, enabling timely diagnosis and treatment initiation in clinical settings, emergency departments, and point-of-care environments, thereby leading to the segmental growth.

The enteric disease testing market by end-use is categorized into hospitals, diagnostic laboratories, research & academic institutes, and other end-users. The hospitals segment accounted for majority revenue share and was valued at around USD 1.4 billion revenue size in 2023.

  • Hospitals are the first place of contact for patients seeking medical attention for gastrointestinal symptoms such as diarrhea, vomiting, abdominal discomfort, and fever, that can suggest enteric infections. Prompt and accurate diagnosis of enteric disorders is critical for identifying the underlying microorganisms, evaluating disease severity, and guiding suitable treatment methods in hospitalized patients.
  • Moreover, hospitals provide a wide range of inpatient and outpatient services, including emergency departments, urgent care centers, specialty clinics, and outpatient laboratories, where enteric disease testing can be performed. Inpatients admitted with suspected enteric infections, as well as ambulatory patients presenting with gastrointestinal symptoms, may require diagnostic evaluation and testing for enteric pathogens during their hospital stay or outpatient visits.
North America Enteric Disease Testing Market, 2020 – 2032 (USD Billion)

North America enteric disease testing market accounted for USD 1.4 billion revenue in 2023 and is predicted to witness substantial market growth.

  • North America endures an immense burden of enteric diseases, which include foodborne illnesses, waterborne infections, and outbreaks of gastrointestinal infections caused by bacteria, viruses, and parasites. To combat the effect of these conditions on public health, public health authorities and healthcare institutions focus on enteric disease monitoring, prevention, and control initiatives, leading to increased demand for enteric disease testing services.
  • Furthermore, the region offers sophisticated healthcare infrastructure, cutting-edge laboratory facilities, and well-equipped clinical microbiology laboratories that can perform a wide range of enteric disease tests, such as microbiological culture, molecular diagnostics, immunoassays, and rapid diagnostic tests (RDTs). Availability to modern diagnostic technology, automated platforms, and qualified laboratory workers allows for efficient and accurate enteric pathogen testing in clinical and public health settings, thus leading to the region growth.

Enteric Disease Testing Market Share

The enteric disease testing industry is competitive in nature, with various large multinationals and small and mid-sized companies competing in the industry. The development and launch of novel advanced products with improved efficiency and cost-effectiveness is among a key market strategy for manufacturers. Some of the leading industry players including Abbott Laboratories, Becton, Dickinson, and Company, Biomerica, Inc., BIOMÉRIEUX S.A, Bio-Rad Laboratories, Inc., among others have a substantial presence in the market.

Enteric Disease Testing Market Companies

Some of the eminent market participants operating in the enteric disease testing industry include:

  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Biomerica, Inc.
  • Bio-Rad Laboratories, Inc.
  • Cepheid
  • Coris BioConcept
  • DiaSorin S.p.A.
  • Eurofins Scientific SE
  • Merck KGaA
  • Meridian Bioscience
  • Quest Diagnostics Incorporated

Enteric Disease Testing Industry News:

  • In January 2022, Meridian Bioscience, Inc. announced that the Curian Campy test has been approved by the US Food and Drug Administration (FDA).  The Curian Campy test is a rapid qualitative fluorescent immunoassay that detects Campylobacter-specific antigens in human feces, including C. jejuni, C. coli, C. upsaliensis, and C. lari.  The assay was intended to be employed on the Curian immunofluorescent testing platform.

Enteric disease testing market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Disease ($ Mn)

  • Bacterial enteric disease
    • C. difficile
    • E. coli
    • Salmonella
    • Campylobacter
    • Listeria
    • Shigellosis 
  • Viral enteric disease
    • Rotavirus infection
    • Norovirus infection
  • Parasitic enteric disease
    • Giardiasis
    • Amebiasis
    • Cryptosporidiosis

Market, By Test Type ($ Mn)

  • Immunoassay
  • Molecular
  • Conventional
  • Chromatography & spectrometry
  • Other test types

Market, By End-use ($ Mn)

  • Hospitals
  • Diagnostic laboratories
  • Research & academic institutes
  • Other end-users

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Middle East and Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Rest of Middle East and Africa


Authors: Mariam Faizullabhoy , Gauri Wani

Frequently Asked Questions (FAQ) :

Enteric disease testing industry size reached USD 3.7 billion in 2023 and is set to expand at 3.9% CAGR from 2024-2032 driven by the rising prevalence of enteric diseases, growing concerns about food safety, and increasing healthcare expenditure and awareness across the globe.

Enteric disease testing industry from the immunoassay segment is anticipated to witness high demand accounting for USD 1.9 billion in revenue by 2032 as they provide rapid results compared to traditional culture-based methods or molecular diagnostics.

North America enteric disease testing industry size generated USD 1.4 billion in 2023 and is set to expand at a robust CAGR through 2032 owing to the presence of a sophisticated healthcare infrastructure, cutting-edge laboratory facilities, and well-equipped clinical microbiology laboratories.

Some of the leading enteric disease testing companies are Abbott Laboratories, Becton, Dickinson, and Company, Biomerica, Inc., BIOMÉRIEUX S.A, Bio, Rad Laboratories, Inc., Cepheid, DiaSorin S.p.A., Eurofins Scientific SE, Merck KGaA, Meridian Bioscience, and Quest Diagnostics Incorporated.

Enteric Disease Testing Market Scope

Buy Now

Premium Report Details

  • Base Year: 2023
  • Companies covered: 12
  • Tables & Figures: 397
  • Countries covered: 22
  • Pages: 228
 Download Free Sample